SUPPLEMENT
Q2 2021 — Reconciliation of Non-GAAP Financial Measures
Q2 2021PDF · 6 pages191 KB
Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2021 2020 2021 2020 Net Earnings, after tax- as reported $6,278 $3,626 $12,475 $9,422 Pre-tax Adjustments Intangible Asset Amortization expense 1,202 1,127 2,417 2,245 Litigation related (23) 613 (23) 733 IPR&D - 6 - 6 Restructuring related 108 115 212 233 Acquisition, integration and divestiture related ¹ 14 29 (524) (933) Unrealized (gains)/losses on securities (243) (533) (208) (206) Medical Device Regulation 56 37 102 51 Other - 3 - 3 Tax Adjustments Tax impact on special item adjustments 2 (135) (253) (248) (520) Tax legislation and other tax related (632) (324) (654) (434) Adjusted Net Earnings, after tax $6,625 $4,446 $13,549 $10,600 Average shares outstanding (Diluted) 2,671.6 2,665.5 2,674.0 2,671.0 Adjusted net earnings per share (Diluted) $2.48 $1.67 $5.07 $3.97 Operational adjusted net earnings per share (Diluted) $2.42 $4.91 Notes: 1 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Second Quarter Six Months Ended Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. The six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. -- 1 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 13.3% 17.2% 62.7% 27.1% U.S. 12.4% 12.2% 77.2% 24.9% International 14.1% 23.7% 51.6% 29.5% WW Currency 4.1 3.6 5.5 4.1 U.S. - - - - International 7.8 8.3 9.7 8.6 WW Operational 9.2% 13.6% 57.2% 23.0% U.S. 12.4% 12.2% 77.2% 24.9% International 6.3% 15.4% 41.9% 20.9% General Surgery Advanced Sterilization Products 1.2 0.2 U.S. 0.0 0.0 International 1.9 0.4 All Other Acquisitions and Divestitures 0.8 0.6 0.3 0.6 U.S. 0.6 (0.1) 0.7 0.1 International 1.1 1.5 0.0 1.0 WW Adjusted Operational 10.0% 14.1% 58.7% 23.8% U.S. 13.0% 12.1% 77.9% 25.1% International 7.4% 16.8% 43.8% 22.4% Adjusted Operational Sales Growth SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 5.2% 13.3% 32.7% 16.9% U.S. 2.0% 9.3% 33.5% 13.8% International 8.1% 18.3% 31.9% 20.3% WW Currency 2.5 3.0 4.0 3.2 U.S. - - - - International 4.8 6.9 7.4 6.6 WW Operational 2.7% 10.3% 28.7% 13.7% U.S. 2.0% 9.3% 33.5% 13.8% International 3.3% 11.4% 24.5% 13.7% General Surgery Advanced Sterilization Products 0.8 0.2 U.S. 0.0 0.0 International 1.5 0.4 All Other Acquisitions and Divestitures 0.6 0.5 0.2 0.4 U.S. 0.5 (0.1) 0.5 0.1 International 0.7 1.2 0.0 0.8 WW Adjusted Operational 3.3% 10.7% 29.7% 14.4% U.S. 2.5% 9.2% 33.9% 13.9% International 4.0% 12.6% 26.0% 14.8% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL Segments -- 3 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income Before Tax by Segment $ 804 32 4,356 4,514 1,746 (354) (244) (252) 6,662 3,940 % to Sales 21.5% 1.0% 34.6% 42.0% 25.0% -8.3% -1.0% -1.4% 28.6% 21.5% Intangible asset amortization expense 105 102 842 779 255 246 - - 1,202 1,127 In-process research and development - - - - - 6 - - - 6 Litigation related 122 638 (81) (58) (64) 33 - - (23) 613 - - - Unrealized loss/(gain) on securities (18) - (151) (522) (74) (11) - - (243) (533) Restructuring related 27 20 17 21 64 74 - - 108 115 Acquisition, integration and divestiture related - - - 10 14 19 - - 14 29 Medical Device Regulation - - - - 56 37 - - 56 37 Other - - - - - 3 - - - 3 Adjusted Income Before Tax by Segment $ 1,040 792 4,983 4,744 1,997 53 (244) (252) 7,776 5,337 % to Sales 27.8% 24.0% 39.6% 44.1% 28.6% 1.2% -1.0% -1.4% 33.4% 29.1% *Estimated as of 07/21/2021. Q2 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 4 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income Before Tax by Segment $ 1,592 802 9,579 8,348 3,375 1,671 (455) (372) 14,091 10,449 % to Sales 21.9% 11.6% 38.6% 38.1% 24.9% 16.4% -1.0% -1.0% 30.9% 26.8% Intangible asset amortization expense 211 202 1,698 1,550 508 493 - - 2,417 2,245 In-process research and development - - - - - 6 - - - 6 Litigation related 122 638 (81) 35 (64) 60 - - (23) 733 Unrealized loss/(gain) on securities (20) 1 (114) (208) (74) 1 - - (208) (206) Restructuring related 55 38 37 41 120 154 - - 212 233 Acquisition, integration and divestiture related - - (570) 19 46 (952) - - (524) (933) Medical Device Regulation - - - - 102 51 - - 102 51 Other - - - - - 3 - - - 3 Adjusted Income Before Tax by Segment $ 1,960 1,681 10,549 9,785 4,013 1,487 (455) (372) 16,067 12,581 % to Sales 26.9% 24.3% 42.5% 44.7% 29.6% 14.6% -1.0% -1.0% 35.2% 32.2% *Estimated as of 07/21/2021. Q2 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 5 of 6 -- Second Quarter Second Quarter July 4, 2021 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other July 4, 2021 Non-GAAP Cost of products sold 7,587 $ (1,202) (20) (20) 6,345 Selling, marketing and admin expenses 6,073 (6) 6,067 Research and development expense 3,394 - (30) 3,364 Other (Income) / Expense (488) - 23 (32) (14) 243 - (268) In-process research and development - - - Restructuring 56 (56) - Provision for taxes on income 384 163 (1) - 17 3 (57) 10 632 - 1,151 Net Earnings 6,278 1,039 (22) - 91 11 (186) 46 (632) - 6,625 Second Quarter Second Quarter June 28, 2020 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other June 28, 2020 Non-GAAP Cost of products sold 6,579 $ (1,127) (22) (8) 5,422 Selling, marketing and admin expenses 4,993 (6) 4,987 Research and development expense 2,707 (5) (23) 2,679 Other (Income) / Expense 24 - (613) (32) (24) 533 (3) (115) In-process research and development 6 (6) - Restructuring 61 (61) - Provision for taxes on income 314 217 123 1 22 4 (122) 7 324 1 891 Net Earnings 3,626 910 490 5 93 25 (411) 30 (324) 2 4,446 Six Months Six Months July 4, 2021 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other July 4, 2021 Non-GAAP Cost of products sold 14,650 $ (2,417) (47) (37) 12,149 Selling, marketing and admin expenses 11,505 (11) 11,494 Research and development expense 6,572 - (54) 6,518 Other (Income) / Expense (1,370) - 23 (56) 524 208 - (671) In-process research and development - - - Restructuring 109 (109) - Provision for taxes on income 1,616 340 (1) - 37 (98) (49) 19 654 - 2,518 Net Earnings 12,475 2,077 (22) - 175 (426) (159) 83 (654) - 13,549 Six Months Six Months June 28, 2020 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other June 28, 2020 Non-GAAP Cost of products sold 13,641 $ (2,245) (37) (22) 11,337 Selling, marketing and admin expenses 10,196 (6) 10,190 Research and development expense 5,287 (5) (23) 5,259 Other (Income) / Expense (655) - (733) (77) 938 206 (3) (324) In-process research and development 6 (6) - Restructuring 119 (119) - Provision for taxes on income 1,027 363 143 1 43 7 (47) 9 434 1 1,981 Net Earnings 9,422 1,882 590 5 190 (940) (159) 42 (434) 2 10,600 (1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. 2020 primarily includes a $983 million Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. In-process research and development Acquisition, integration and divestiture related (1) Unrealized (loss)/gain on securities Tax legislation and other tax related In-process research and development Acquisition, integration and divestiture related Unrealized (loss)/gain on securities Tax legislation and other tax related Year to Date In-process research and development Acquisition, integration and divestiture related (1) Unrealized (loss)/gain on securities Tax legislation and other tax related Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development Acquisition, integration and divestiture related Unrealized (loss)/gain on securities Tax legislation and other tax related -- 6 of 6 --